Reflecting on advancing cancer treatment through research and innovation – Sarah Cannon Research Institute

Sarah Cannon Research Institute shared the following on LinkedIn:

“Today, on World Cancer Research Day, Sarah Cannon Research Institute proudly reflects on our work to advance cancer treatment through research and innovation.

With more than 1,000 trials actively enrolling, our commitment to advancing cancer therapies for patients is at the center of everything we do. Our team of over 1,300 dedicated research physicians works tirelessly to bring new hope to patients and their families.

We are honored to have participated in the development of the majority of FDA-approved cancer therapies available.

With 750+ first-in-human trials conducted at SCRI, we aim to make the latest cutting-edge therapies accessible to patients across the U.S.

Each year, we register more than 4,500 patients to enroll in our trials, providing access to treatments for patients, closer to home.

Together, we are making strides in the fight against cancer. Thank you for your continued support and partnership in our mission to bring hope and healing to those affected by this disease.”

Source: Sarah Cannon Research Institute/LinkedIn